Floatz logo

Alintegimod

Renal Cell Cancer

7 Hills Pharma, LLCSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Renal Cell Cancer cohort.

Asset / SponsorPhaseRating
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB
Zoledronate
Novartis Pharmaceuticals
Phase 4BB
Evomela
St. Jude Children's Research Hospital
Phase 2B
Ciforadenant
M.D. Anderson Cancer Center
Phase 1/2B
VINBLASTINE
Hoffmann-La Roche
Phase 2B

View all 24 →

Same molecule, other indications

Alintegimod is also rated in:

Anaplastic Lymphoma Kinase Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →
ALK Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →
MSI-HighDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →